Influence of polymorphisms in xenobiotic-metabolizing genes and DNA-repair genes on diepoxybutane-induced SCE frequency

Environmental and Molecular Mutagenesis

Volumn 47, Issue 9, 2006, Pages 666-673

  Laczmanska, Izabela ^a   Gil, Justyna ^a   Karpinski, Pawel ^a   Stembalska, Agnieszka ^a   Kozlowska, Joanna ^a   Busza, Halina ^a   Trusewicz, Alicja ^a   Pesz, Karolina ^a   Ramsey, David ^b   Schlade Bartusiak, Kamila ^c   Blin, Nikolaus ^d   Sasiadek, Maria Malgorzata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

DEB genotoxicity; Genetic susceptibility; Mutagenesis

Indexed keywords

ADENINE; ARGININE; ARYLAMINE ACETYLTRANSFERASE; BRCA1 PROTEIN; BUTADIENE DIEPOXIDE; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; DNA; EPOXIDE HYDROLASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE T1; GUANINE; HELICASE; HISTIDINE; NIBRIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN XPA; PROTEIN XPF; PROTEIN XPG; PROTEIN XRCC1; PROTEIN XRCC2; PROTEIN XRCC3; RAD51 PROTEIN; TYROSINE; XENOBIOTIC AGENT; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER GENETICS; CHEMICAL MUTAGENESIS; CODON; CONTROLLED STUDY; CYP1A1 GENE; CYP2E1 GENE; DNA REPAIR; EPHX GENE; ERCC1 GENE; FEMALE; GENE; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTOXICITY; GENOTYPE; GSTT1 GENE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INDUCED MUTATION; LYMPHOCYTE; MALE; MUTAGENICITY; NAT2 GENE; NBS1 GENE; NORMAL HUMAN; ONCOGENE; RAD51 GENE; SISTER CHROMATID EXCHANGE; XENOBIOTIC METABOLISM; XPA GENE; XPC GENE; XPD GENE; XPF GENE; XPG GENE; XRCC1 GENE; XRCC2 GENE; XRCC3 GENE;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; DNA REPAIR; DNA-BINDING PROTEINS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOCYTES; MALE; MUTAGENS; POLYMORPHISM, GENETIC; SISTER CHROMATID EXCHANGE; XENOBIOTICS;

EID: 33845510391     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20253     Document Type: Article

References (52)

1. Abdel-Rahman SZ, Ammenheuser MM, Ward JB Jr. 2001. Human sensitivity to 1,3-butadiene: Role of microsomal epoxide hydrolase polymorphisms. Carcinogenesis 22:415-423.
2. Agundez JA. 2004. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 5:211-224.
3. Ahmad NN, Cu-Unjieng AB, Donoso LA. 1995. Modification of standard proteinase K/phenol method for DNA isolation to improve yield and purity from frozen blood. J Med Genet 32:129-130.
4. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra-Torres CH, Salama SA, Alpard SK, Tyring SK. 2003. Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genet Cytogenet 145:97-102.
5. Chan PC, Wong BY, Ozcelik H, Cole DE. 1999. Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR. Clin Chem 45:1285-1287.
6. Chen YC, Hunter DJ. 2005. Molecular epidemiology of cancer. CA Cancer J Clin 55:45-54.
7. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. 2000. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843-847.
8. Cocchi L, Scarcelli V, Puliti A, Barale R, Sbrana I. 2005. Endogenous sex hormones affect the mutagen-induced chromosome damage by altering a caffeine-sensitive checkpoint. Mutat Res 570:281-288.
9. Csanady GA, Guengerich FP, Bond JA. 1992. Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. Carcinogenesis 13:1143-1153.
10. (Erratum: Carcinogenesis 1993 14:784).
11. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA. 1999. Polymorphisms in the DNA repair gene XPD: Correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 8:77-81.
12. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. 2005. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 574:112-123.
13. Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, Melhem MF, Keohavong P. 2003. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 24:1671-1676.
14. Georgiadis P, Topinka J, Vlachodimitropoulos D, Stoikidou M, Gioka M, Stephanou G, Autrup H, Demopoulos NA, Katsouyanni K, Sram R, Kyrtopoulos SA. 2005. Interactions between CYP1A1 polymorphisms and exposure to environmental tobacco smoke in the modulation of lymphocyte bulky DNA adducts and chromosomal aberrations. Carcinogenesis 26:93-101.
15. Grzybowska E, Sieminska M. Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, Rogozinska-Szczepka J, Kazmierczak-Maciejewska M. 2002. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol 49:351-356.
16. Haufroid V, Jakubowski M, Janasik B, Ligocka D, Buchet JP, Bergamaschi E, Manini P, Mutti A, Ghittori S, Arand M, Hangen N, Oesch F, Hirvonen A, Lison D. 2002. Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene. Pharmacogenetics 12:691-702.
17. Hou SM, Lambert B, Hemminki K. 1995. Relationship between hprt mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis 16:1913-1917.
18. Husgafvel-Pursiainen KJ, Maki-Paakkanen, Norppa H, Sorsa M. 1980. Smoking and sister chromatid exchange. Hereditas 92:247-250.
19. Ishikawa H, Yamamoto H, Tian Y, Kawano M, Yamauchi T, Yokoyama K. 2004. Evidence of association of the CYP2E1 genetic polymorphism with micronuclei frequency in human peripheral blood. Mutat Res 546:45-53.
20. Israeli D, Patael Y, Friedman T, Friedman E. 2000. The m2 and m4 polymorphisms in CYP1A1 by NcoI digest-revision of detection method. Hum Mutat 15:120.
21. Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E, Hemminki K. 2003. Single nucleotide polymorphisms in the XPG gene: Determination of role in DNA repair and breast cancer risk. Int J Cancer 103:671-675.
22. Landi S, Norppa H, Frenzilli G, Cipollini G, Ponzanelli I, Barale R, Hirvonen A. 1998. Individual sensitivity to cytogenetic effects of 1,2:3,4-diepoxybutane in cultured human lymphocytes: Influence of glutathione S-transferase M1, P1 and T1 genotypes. Pharmacogenetics 8:461-471.
23. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R. 2001. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98:3232-3236.
24. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA. 2000. XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 21:551-555.
25. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P. 2001. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437-1445.
26. Medina PP, Ahrendt SA, Pollan M, Fernandez P, Sidransky D, Sanchez-Cespedes M. 2003. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. Cancer Epidemiol Biomarkers Prev 12:699-704.
27. Nishimoto IN, Hanaoka T, Sugimura H, Nagura K, Ihara M, Li XJ, Arai T, Hamada GS, Kowalski LP, Tsugane S. 2000. Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: Case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Epidemiol Biomarkers Prev 9:675-680.
28. Norppa H. 2001. Genetic polymorphisms and chromosome damage. Int J Hyg Environ Health 204:31-38.
29. Norppa H. 2003. Genetic susceptibility, biomarker respones, and cancer. Mutat Res 544:339-348.
30. Norppa H. 2004. Cytogenetic biomarkers and genetic polymorphisms. Toxicol Lett 149:309-334.
31. Norppa H, Hirvonen A, Järventaus H, Uusküla M, Tasa G, Ojajärvi A, Sorsa M. 1995. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis 16:1261-1264.
32. Park JY, Park SH, Choi JE, Lee SY, Jeon HS, Cha SI, Kim CH, Park JH, Kam S, Park RW, Kim IS, Jung TH. 2002. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A, risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 11:993-997.
33. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. 2003. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162-166.
34. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. 1994. Human glutathione S-transferase theta (GSTT1): cDNA Cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276.
35. Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M, Meuth M, Thacker J, Cox A. 2002. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair nd breast cancer. Hum Mol Genet 11:1433-1438.
36. Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H. 2001. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer 95:86-91.
37. Roy SK, Trivedi AH, Bakshi SR, Patel SJ, Shukla PH, Bhatavdekar JM, Patel DD, Shah PM. 2000. Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA repair capacity in breast cancer families. J Exp Clin Cancer Res 19:169-173.
38. Salama SA, Sierra-Torres CH, Oh HY, Hamada FA, Au WW. 1999. A multiplex-PCR/RFLP procedure for simultaneous CYP2E1, mEH and GSTM1 genotyping. Cancer Lett 143:51-56.
39. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkstrom H, Larsson P, Kumar R, Hemminki K. 2004. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25:729-734.
40. Sasiadek M, Norppa H, Sorsa M. 1991. 1,3-Butadiene and its epoxides induce sister-chromatid exchanges in human lymphocytes in vitro. Mutat Res 261:117-121.
41. Schlade-Bartusiak K, Rozik K, Laczmanska I, Ramsey D, Sasiadek MM. 2004. Influence of GSTT1, mEH, CYP2E1 and RAD51 polymorphisms on diepoxybutane-induced SCE frequency in cultured human lymphocytes Mutat Res 558:121-130.
42. Schröder KR, Wiebel FA, Reich S, Dannappel D, Bolt HM, Hallier E. 1995. Glutathione-S-transferase (GST) theta polymorphism influences background SCE rate. Arch Toxicol 69:505-507.
43. Seidegard J, DePierre JW. 1983. Microsomal epoxide hydrolase. Properties, regulation and function. Biochim Biophys Acta 695:251-270.
44. Smith TR, Levine EA, Perrier ND, Miller MS, Freimams RI, Lohman K, Case LD, Xu J, Mohrenweiser HW, Hu JJ. 2003. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12:1200-1204.
45. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q. 1999. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 20:2125-2129.
46. Trenz K, Lugowski S, Jahrsdorfer U, Jainta S, Vogel W, Speit G. 2003. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat Res 544:279-288.
47. Tuimala J, Szekely G, Wikman H, Jarventaus H, Hirvonen A, Gundy S, Norppa H. 2004. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: Effects on levels of sister chromatid exchanges and chromosomal aberrations. Mutat Res 554:319-333.
48. Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, de Zwart FA, Natarajan AT, Hemminki K. 2001. Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutat Res 482:89-103.
49. Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, Dusinska M, Kuricova M, Zamecnikova M, Musak L, Buchancova J, Norppa H, Hirvonen A, Vodickova L, Naccarati A, Matousu Z, Hemminki K. 2004. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757-763.
50. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. 1995. Gene deletion of glutathione S-transferase theta: Correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 4:253-259.
51. Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. 2002. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev 11:15-21.
52. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. 2004. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943.